Study guide
Heart failure assessment and treatment
AMC CAT MCQ Examination AMC Part 1
Track your progress as you read
Finished sections get a check mark.
1 Acute Coronary Syndromes & ECG Localization
ACS recognition and ECG localisation Reperfusion and infarction complications
2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias
Heart failure assessment and treatment Arrhythmias and conduction emergencies
3 Systemic Hypertension & Peripheral Vascular Disease
Blood pressure and cardiovascular risk Secondary hypertension and arterial disease
4 Valvular Heart Disease, Infective Endocarditis & Pericarditis
Aortic and mitral valve disease Endocarditis and pericardial emergencies
5 Asthma & COPD Acute Flares and Maintenance
Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations
6 Pneumonia, pleural disease and respiratory failure
Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis
7 GI bleeding, bowel inflammation and malabsorption
GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS
8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis
Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance
9 Diabetes, thyroid and adrenal disease
Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease
10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies
AKI and chronic kidney disease Potassium and sodium emergencies
11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment
Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care
12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis
Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia
13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology
Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms
14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis
Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment
15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries
Trauma primary survey and adjuncts Chest trauma and immediate threats
16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance
Head injury, imaging and haemorrhage Herniation and spinal cord injury
17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome
Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury
18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care
Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus
19 Aortic Aneurysms & Acute Arterial Limb Ischaemia
Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia
20 Urological Emergencies, Testicular Torsion & Haematuria Investigation
Retention, stones and obstructed infection Scrotal pain and haematuria
21 Preoperative Risk Stratification & Postoperative Surgical Complications
Preoperative assessment and medicines Postoperative complications and prevention
22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening
Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons
23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy
Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding
24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies
Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth
25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis
Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care
26 Contraception, Emergency Contraception & Pregnancy Termination
Contraceptive choice and missed pills Emergency contraception and abortion
27 Australian Cervical Screening Program & Gynaecological Malignancies
Cervical screening and cervical cancer Endometrial and ovarian cancer
28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice
Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening
29 Developmental Milestones, Growth Charts & Failure to Thrive
Developmental milestones Regression, autism and support Faltering growth and developmental comparisons
30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions
Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons
31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis
Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis
32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease
Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up
33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury
Pyloric stenosis Intussusception and dehydration Child protection and injury assessment
34 The Mental State Examination & Suicide Risk Stratification
Mental state examination and psychotic symptoms Suicide formulation and mental health law
35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers
Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT
36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder
Anxiety, panic and agoraphobia OCD and trauma-related disorders
37 Schizophrenia, Acute Psychosis & Antipsychotic Management
Psychosis assessment and antipsychotics Clozapine and severe adverse effects
38 Substance Use Disorders & Acute Withdrawal Syndromes
Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants
39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry
Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry
40 Medicare, PBS, AHPRA & Good Medical Practice Framework
Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications
41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment
Consent, material risks and young people Capacity, refusal and substitute decisions
42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications
Privacy, disclosure and child reporting Driving fitness and threat disclosure
43 First Nations health and preventive care
First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention
44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases
Epidemiology, calculations, bias and surveillance
45 Neurological presentations
Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness
46 Musculoskeletal pain
Back, neck, bone and soft tissue pain
47 Eye presentations
Altered vision and retinal disease Red eye, ocular injury and discharge
48 Ear, nose, throat and oral health
Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis
49 Skin, hair and nails
Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities
50 Breast health and feeding
Breast lumps, discharge and breastfeeding problems
51 Sexual and reproductive presentations
Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction
52 Palliative care and carers
The dying patient, symptoms and carers
53 Eating disorders and personality care
Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care
54 Sleep presentations
Insomnia, snoring and daytime sleepiness
55 Poisoning, resuscitation and environmental emergencies
Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning
56 Communication, rights and professional practice
Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health
57 Genetics, research and donation
Genetic testing, research and organ donation
58 Travel, fever and outbreaks
Fever, travellers and outbreak response
Heart failure assessment and treatment
Key Takeaways Explain This Topic AI
HFrEF therapy combines appropriate renin–angiotensin treatment, beta blockade, mineralocorticoid antagonism and SGLT2 inhibition.
Start and increase beta blockers when the patient is clinically stable.
NT-proBNP is easier to interpret than BNP during sacubitril/valsartan treatment.
Last updated: October 2026
Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias
Heart failure (HF) and cardiac arrhythmias represent major causes of emergency hospital admissions and cardiovascular morbidity across Australia. Effective management requires precise phenotypic classification, rapid initiation of mortality-reducing guideline-directed medical therapy (GDMT), and timely stabilization of haemodynamic decompensation and electrical instability.
Heart Failure Phenotypes and Diagnostic Evaluation
Heart failure is a complex clinical syndrome characterized by cardinal symptoms (breathlessness, orthopnoea, fatigue, ankle swelling) and clinical signs (elevated jugular venous pressure, pulmonary crackles, peripheral oedema) caused by a structural or functional cardiac abnormality that results in elevated intracardiac pressures or reduced cardiac output.
According to the universal definition and Australian guidelines, heart failure is classified into three distinct phenotypes based on left ventricular ejection fraction (LVEF):
Heart Failure with Reduced Ejection Fraction (HFrEF) : L V E F ≤ 40 % LVEF \le 40\% L V EF ≤ 40% . Characterized by impaired myocardial contractility, progressive ventricular dilatation, and eccentric remodelling. Quadruple medical therapy substantially reduces mortality and hospital admissions.
Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF) : L V E F 41 % to 49 % LVEF \text{ } 41\%\text{ to }49\% L V EF 41% to 49% . Represents a transitional phenotype that shares clinical characteristics and therapeutic responsiveness with HFrEF.
Heart Failure with Preserved Ejection Fraction (HFpEF) : L V E F ≥ 50 % LVEF \ge 50\% L V EF ≥ 50% with objective evidence of diastolic dysfunction, structural alterations (left atrial enlargement, left ventricular hypertrophy), or elevated resting/exertional left ventricular filling pressures.
Diagnostic Biomarkers & Imaging
B-type Natriuretic Peptide (BNP) & N-Terminal pro-BNP (NT-proBNP) : Released by ventricular myocytes in response to increased wall stress and volume expansion. Highly sensitive rule-out biomarkers in the acute presentation:
Acute setting: B N P < 100 pg/mL BNP < 100\text{ pg/mL} BNP < 100 pg/mL or N T - p r o B N P < 300 pg/mL NT\text{-}proBNP < 300\text{ pg/mL} NT - p ro BNP < 300 pg/mL reliably excludes acute heart failure (negative predictive value > 95 % > 95\% > 95% ).
Confounders: Levels are elevated by advanced age, renal impairment ( e G F R < 60 mL/min/1.73m 2 eGFR < 60\text{ mL/min/1.73m}^2 e GFR < 60 mL/min/1.73m 2 ), and atrial fibrillation. Conversely, levels are disproportionately lower in obese patients ( B M I ≥ 30 kg/m 2 BMI \ge 30\text{ kg/m}^2 BM I ≥ 30 kg/m 2 ).
Clinical Caveat : Sacubitril inhibits neprilysin (the enzyme that degrades BNP). Consequently, patients receiving sacubitril/valsartan have elevated circulating BNP levels; NT-proBNP must be measured instead to assess clinical response, as NT-proBNP is not a neprilysin substrate.
Transthoracic Echocardiography (TTE) : The gold standard non-invasive diagnostic investigation. Evaluates LVEF, chamber dimensions, regional wall motion abnormalities, valvular lesions, and markers of diastolic filling pressures (mitral inflow E / A E/A E / A ratio, tissue Doppler E / e ′ E/e' E / e ′ ratio, and tricuspid regurgitant jet velocity for estimating pulmonary artery systolic pressure).
Chest Radiography : Identifies signs of pulmonary venous congestion and fluid overload:
Cardiomegaly: Cardiothoracic ratio > 0.50 > 0.50 > 0.50 on a posterior-anterior view.
Vascular redistribution: Upper lobe venous diversion ("stag's antler sign").
Interstitial oedema: Peribronchial cuffing and horizontal linear densities at the lung bases ( Kerley B lines ).
Alveolar oedema: Bilateral perihilar opacities in a classic "bat-wing" or "butterfly" distribution.
Pleural effusions: Usually bilateral or right-sided greater than left-sided.
Guideline-Directed Medical Therapy (GDMT) for HFrEF
Australian guidelines (NHFA/CSANZ) endorse early, concurrent initiation and up-titration of the "Fantastic Four" foundational pillars of quadruple therapy for all patients with HFrEF ( L V E F ≤ 40 % LVEF \le 40\% L V EF ≤ 40% ) to reduce mortality and hospitalizations:
Angiotensin Receptor-Neprilysin Inhibitor (ARNI) or ACE Inhibitor :
Sacubitril/valsartan is preferred first-line over ACE inhibitors based on the landmark PARADIGM-HF trial, which demonstrated a 20% relative reduction in cardiovascular death and heart failure hospitalization.
Critical Safety Rule : When switching a patient from an ACE inhibitor to sacubitril/valsartan, a mandatory 36-hour washout period is required between the last dose of the ACE inhibitor and the first dose of sacubitril/valsartan. Concomitant inhibition of ACE and neprilysin results in excessive bradykinin accumulation, causing catastrophic, life-threatening angioedema. A washout period is not required when switching from an Angiotensin Receptor Blocker (ARB).
If ARNI is not tolerated or subsidized, an ACE inhibitor (e.g., ramipril, perindopril) or ARB (e.g., candesartan) should be titrated to target doses.
Evidence-Based Beta-Blockers :
HFrEF beta-blockade: Use an agent supported by heart failure evidence and titrate in a stable patient. Choice depends on comorbidity, blood pressure and local guidance; avoid presenting a short list as the only agents with any evidence.
Must be initiated at low doses only when the patient is clinically stable and euvolaemic , with slow dose doubling every 2 to 4 weeks under close observation for transient fluid retention.
Mineralocorticoid Receptor Antagonists (MRAs) :
Spironolactone ( 25 to 50 mg 25\text{ to }50\text{ mg} 25 to 50 mg daily) or eplerenone ( 25 to 50 mg 25\text{ to }50\text{ mg} 25 to 50 mg daily).
Serum potassium and creatinine must be checked at baseline, 1 week, 4 weeks, and then every 3 months. Therapy must be withheld or dose halved if serum potassium exceeds 5.5 mmol/L 5.5\text{ mmol/L} 5.5 mmol/L or if renal function declines acutely.
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors :
Dapagliflozin ( 10 mg 10\text{ mg} 10 mg once daily) or empagliflozin ( 10 mg 10\text{ mg} 10 mg once daily).
SGLT2 inhibitors reduce heart-failure events across reduced, mildly reduced and preserved ejection fractions. Do not describe the composite benefit as proof of mortality reduction alone in every phenotype; also manage congestion and comorbid disease.
Device Therapies in HFrEF
Implantable Cardioverter-Defibrillator (ICD) : Indicated for primary prevention of sudden cardiac death in patients with symptomatic HFrEF ( L V E F ≤ 35 % LVEF \le 35\% L V EF ≤ 35% , NYHA Class II–III) despite at least 3 months of optimal GDMT, provided expected meaningful survival exceeds 1 year.
Cardiac Resynchronization Therapy (CRT-P / CRT-D) : Indicated for patients with L V E F ≤ 35 % LVEF \le 35\% L V EF ≤ 35% , sinus rhythm, and complete Left Bundle Branch Block (LBBB) with a QRS duration ≥ 130 to 150 ms \ge 130\text{ to }150\text{ ms} ≥ 130 to 150 ms despite optimal medical therapy, to restore ventricular mechanical synchrony.
Acute Decompensated Heart Failure & Cardiogenic Shock
Acute decompensated heart failure (ADHF) is classified using the Stevenson 2x2 hemodynamic matrix based on clinical bedside evaluation of perfusion ("warm" vs "cold") and congestion ("dry" vs "wet"):
Warm & Wet (Most Common, ~80%) : Adequate peripheral perfusion with pulmonary and systemic congestion (elevated JVP, crepitations, peripheral oedema). Managed with intravenous loop diuretics and vasodilators.
Cold & Wet (Cardiogenic Shock, ~10%) : Poor peripheral perfusion (hypotension, oliguria, cold mottled extremities, altered mental status, lactic acidosis) with systemic congestion. Requires inotropic support, vasopressors, and mechanical circulatory support.
Cold & Dry (~5%) : Hypoperfusion without congestion. Typically results from excessive diuresis; requires cautious fluid resuscitation.
Warm & Dry (~5%) : Compensated, euvolaemic state on optimal therapy.
Emergency Management of Acute Pulmonary Oedema
Positioning & Oxygenation : Sit the patient fully upright. Administer supplemental oxygen only if S p O 2 < 93 % SpO_2 < 93\% Sp O 2 < 93% .
Non-invasive ventilation: In appropriate acute cardiogenic pulmonary oedema, positive airway pressure recruits alveoli, reduces respiratory work and can reduce cardiac loading. It requires close monitoring; shock, inability to protect the airway or failure to improve may require another approach.
Intravenous Loop Diuretics : Administer intravenous furosemide ( 40 to 80 mg 40\text{ to }80\text{ mg} 40 to 80 mg IV bolus, or 1 to 2 times 1\text{ to }2\text{ times} 1 to 2 times the patient's daily home oral dose). Diuretics produce rapid venodilation within minutes, followed by diuresis at 20 to 30 minutes.
Intravenous Vasodilators : If systolic blood pressure is > 110 mmHg > 110\text{ mmHg} > 110 mmHg , administer sublingual or intravenous glyceryl trinitrate (starting at 10 to 20 mcg/min 10\text{ to }20\text{ mcg/min} 10 to 20 mcg/min and titrating upward every 3 to 5 minutes). Nitrates rapidly reduce systemic venous return (preload) and left ventricular filling pressures.
Opioid Policy : Routine administration of intravenous morphine is no longer recommended in Australian acute heart failure guidelines, as registry data demonstrate an association with increased intubation rates, ICU admissions, and in-hospital mortality.
Primary references (checked 7 October 2026): Heart Foundation AF resources .